478 related articles for article (PubMed ID: 25936528)
1. The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL.
Vasyutina E; Boucas JM; Bloehdorn J; Aszyk C; Crispatzu G; Stiefelhagen M; Breuer A; Mayer P; Lengerke C; Döhner H; Beutner D; Rosenwald A; Stilgenbauer S; Hallek M; Benner A; Herling M
Leukemia; 2015 Oct; 29(10):2003-14. PubMed ID: 25936528
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia.
Cui B; Chen L; Zhang S; Mraz M; Fecteau JF; Yu J; Ghia EM; Zhang L; Bao L; Rassenti LZ; Messer K; Calin GA; Croce CM; Kipps TJ
Blood; 2014 Jul; 124(4):546-54. PubMed ID: 24914134
[TBL] [Abstract][Full Text] [Related]
3. PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.
Motiwala T; Kutay H; Zanesi N; Frissora FW; Mo X; Muthusamy N; Jacob ST
Leukemia; 2015 Jun; 29(6):1350-9. PubMed ID: 25482129
[TBL] [Abstract][Full Text] [Related]
4. SUMO1 negatively regulates the transcriptional activity of EVI1 and significantly increases its co-localization with EVI1 after treatment with arsenic trioxide.
Singh S; Pradhan AK; Chakraborty S
Biochim Biophys Acta; 2013 Oct; 1833(10):2357-68. PubMed ID: 23770046
[TBL] [Abstract][Full Text] [Related]
5. The miR-17∼92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes.
Bomben R; Gobessi S; Dal Bo M; Volinia S; Marconi D; Tissino E; Benedetti D; Zucchetto A; Rossi D; Gaidano G; Del Poeta G; Laurenti L; Efremov DG; Gattei V
Leukemia; 2012 Jul; 26(7):1584-93. PubMed ID: 22343732
[TBL] [Abstract][Full Text] [Related]
6. EVI1 promotes tumor growth via transcriptional repression of MS4A3.
Heller G; Rommer A; Steinleitner K; Etzler J; Hackl H; Heffeter P; Tomasich E; Filipits M; Steinmetz B; Topakian T; Klingenbrunner S; Ziegler B; Spittler A; Zöchbauer-Müller S; Berger W; Wieser R
J Hematol Oncol; 2015 Mar; 8():28. PubMed ID: 25886616
[TBL] [Abstract][Full Text] [Related]
7. The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL.
Stachelscheid J; Jiang Q; Aszyk C; Warner K; Bley N; Müller T; Vydzhak O; Symeonidis K; Crispatzu G; Mayer P; Blakemore SJ; Goehring G; Newrzela S; Hippler S; Robrecht S; Kreuzer KA; Pallasch C; Krüger M; Lechner A; Fischer K; Stilgenbauer S; Beutner D; Hallek M; Auguin D; Hüttelmaier S; Bloehdorn J; Vasyutina E; Herling M
Blood; 2023 Mar; 141(12):1425-1441. PubMed ID: 36179280
[TBL] [Abstract][Full Text] [Related]
8. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis.
Tanaka M; Suzuki HI; Shibahara J; Kunita A; Isagawa T; Yoshimi A; Kurokawa M; Miyazono K; Aburatani H; Ishikawa S; Fukayama M
Oncogene; 2014 May; 33(19):2454-63. PubMed ID: 23752186
[TBL] [Abstract][Full Text] [Related]
9. Expression and function of the TL1A/DR3 axis in chronic lymphocytic leukemia.
Cavallini C; Lovato O; Bertolaso A; Zoratti E; Malpeli G; Mimiola E; Tinelli M; Aprili F; Tecchio C; Perbellini O; Scarpa A; Zamò A; Cassatella MA; Pizzolo G; Scupoli MT
Oncotarget; 2015 Oct; 6(31):32061-74. PubMed ID: 26393680
[TBL] [Abstract][Full Text] [Related]
10. Modifying akt signaling in B-cell chronic lymphocytic leukemia cells.
Hofbauer SW; Piñón JD; Brachtl G; Haginger L; Wang W; Jöhrer K; Tinhofer I; Hartmann TN; Greil R
Cancer Res; 2010 Sep; 70(18):7336-44. PubMed ID: 20823161
[TBL] [Abstract][Full Text] [Related]
11. miR-133 regulates Evi1 expression in AML cells as a potential therapeutic target.
Yamamoto H; Lu J; Oba S; Kawamata T; Yoshimi A; Kurosaki N; Yokoyama K; Matsushita H; Kurokawa M; Tojo A; Ando K; Morishita K; Katagiri K; Kotani A
Sci Rep; 2016 Jan; 6():19204. PubMed ID: 26754824
[TBL] [Abstract][Full Text] [Related]
12. p53-dependent non-coding RNA networks in chronic lymphocytic leukemia.
Blume CJ; Hotz-Wagenblatt A; Hüllein J; Sellner L; Jethwa A; Stolz T; Slabicki M; Lee K; Sharathchandra A; Benner A; Dietrich S; Oakes CC; Dreger P; te Raa D; Kater AP; Jauch A; Merkel O; Oren M; Hielscher T; Zenz T
Leukemia; 2015 Oct; 29(10):2015-23. PubMed ID: 25971364
[TBL] [Abstract][Full Text] [Related]
13. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.
Balgobind BV; Lugthart S; Hollink IH; Arentsen-Peters ST; van Wering ER; de Graaf SS; Reinhardt D; Creutzig U; Kaspers GJ; de Bont ES; Stary J; Trka J; Zimmermann M; Beverloo HB; Pieters R; Delwel R; Zwaan CM; van den Heuvel-Eibrink MM
Leukemia; 2010 May; 24(5):942-9. PubMed ID: 20357826
[TBL] [Abstract][Full Text] [Related]
14. Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts.
Mesquita D; Barros-Silva JD; Santos J; Skotheim RI; Lothe RA; Paulo P; Teixeira MR
Oncotarget; 2015 Mar; 6(7):5217-36. PubMed ID: 25595908
[TBL] [Abstract][Full Text] [Related]
15. miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.
Sharma S; Pavlasova GM; Seda V; Cerna KA; Vojackova E; Filip D; Ondrisova L; Sandova V; Kostalova L; Zeni PF; Borsky M; Oppelt J; Liskova K; Kren L; Janikova A; Pospisilova S; Fernandes SM; Shehata M; Rassenti LZ; Jaeger U; Doubek M; Davids MS; Brown JR; Mayer J; Kipps TJ; Mraz M
Blood; 2021 May; 137(18):2481-2494. PubMed ID: 33171493
[TBL] [Abstract][Full Text] [Related]
16. Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia.
Sivina M; Hartmann E; Vasyutina E; Boucas JM; Breuer A; Keating MJ; Wierda WG; Rosenwald A; Herling M; Burger JA
Leukemia; 2012 Aug; 26(8):1812-20. PubMed ID: 22460735
[TBL] [Abstract][Full Text] [Related]
17. EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2.
Gómez-Benito M; Conchillo A; García MA; Vázquez I; Maicas M; Vicente C; Cristobal I; Marcotegui N; García-Ortí L; Bandrés E; Calasanz MJ; Alonso MM; Odero MD
Br J Cancer; 2010 Oct; 103(8):1292-6. PubMed ID: 20842122
[TBL] [Abstract][Full Text] [Related]
18. miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.
Bresin A; Callegari E; D'Abundo L; Cattani C; Bassi C; Zagatti B; Narducci MG; Caprini E; Pekarsky Y; Croce CM; Sabbioni S; Russo G; Negrini M
Oncotarget; 2015 Aug; 6(23):19807-18. PubMed ID: 26090867
[TBL] [Abstract][Full Text] [Related]
19. ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia.
Joshi AD; Hegde GV; Dickinson JD; Mittal AK; Lynch JC; Eudy JD; Armitage JO; Bierman PJ; Bociek RG; Devetten MP; Vose JM; Joshi SS
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5295-304. PubMed ID: 17875758
[TBL] [Abstract][Full Text] [Related]
20. The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid.
Steinmetz B; Hackl H; Slabáková E; Schwarzinger I; Smějová M; Spittler A; Arbesu I; Shehata M; Souček K; Wieser R
Cell Cycle; 2014; 13(18):2931-43. PubMed ID: 25486480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
